Fidelity Advisor Biotechnology Fund C (FBTCX)
19.93
+0.47
(+2.42%)
USD |
Jun 02 2025
Key Stats
Customize
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 1.71% | 1.276B | 1.31% | 73.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -261.05M | -5.35% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The Fund seeks capital appreciation by investing at least 80% of its assets in equity securities of firms engaged in research, development, distribution, and manufacture of various biotech products, services, and processes and firms benefiting from advances in biotechnology. Issuers may be foreign or domestic. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Fidelity Investments |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
87
-243.05M
Peer Group Low
67.23M
Peer Group High
1 Year
% Rank:
74
-261.05M
-2.441B
Peer Group Low
28.78M
Peer Group High
3 Months
% Rank:
82
-714.92M
Peer Group Low
8.653M
Peer Group High
3 Years
% Rank:
82
-7.035B
Peer Group Low
90.54M
Peer Group High
6 Months
% Rank:
84
-1.668B
Peer Group Low
12.97M
Peer Group High
5 Years
% Rank:
86
-6.554B
Peer Group Low
4.803B
Peer Group High
YTD
% Rank:
84
-1.192B
Peer Group Low
15.76M
Peer Group High
10 Years
% Rank:
87
-11.92B
Peer Group Low
5.551B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of June 03, 2025.
Asset Allocation
As of March 31, 2025.
| Type | % Net |
|---|---|
| Cash | 0.28% |
| Stock | 98.17% |
| Bond | 0.11% |
| Convertible | 0.00% |
| Preferred | 1.44% |
| Other | 0.00% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| AbbVie Inc | 19.28% | 187.28 | 0.16% |
| Gilead Sciences Inc | 9.00% | 109.32 | 0.38% |
| Regeneron Pharmaceuticals Inc | 6.58% | 487.63 | -0.65% |
| Alnylam Pharmaceuticals Inc | 5.88% | 303.73 | -0.77% |
| Ascendis Pharma AS | 5.42% | 174.44 | -0.71% |
| Amgen Inc | 4.96% | 289.59 | 0.39% |
| argenx SE | 4.63% | 576.79 | -1.34% |
| Nuvalent Inc | 2.29% | 78.21 | 1.33% |
| Neurocrine Biosciences Inc | 2.16% | 125.02 | 0.37% |
| Xenon Pharmaceuticals Inc | 1.99% | 30.69 | 2.06% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | 1.00% |
| Actual Management Fee | 0.70% |
| Administration Fee | -- |
| Maximum Front Load | -- |
| Maximum Deferred Load | 1.00% |
| Maximum Redemption Fee | 0.00% |
| General Availability | |
| Available for Insurance Product | -- |
| Available for RRSP | -- |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 0.00 None |
| Minimum Subsequent Investment | 0.00 None |
Basic Info
| Investment Strategy | |
| The Fund seeks capital appreciation by investing at least 80% of its assets in equity securities of firms engaged in research, development, distribution, and manufacture of various biotech products, services, and processes and firms benefiting from advances in biotechnology. Issuers may be foreign or domestic. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Fidelity Investments |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (6-2-25) | 3.03% |
| 30-Day SEC Yield (10-3-23) | 0.00% |
| 7-Day SEC Yield (10-3-23) | 0.00% |
| Stock | |
| Weighted Average PE Ratio | 49.32 |
| Weighted Average Price to Sales Ratio | 14.50 |
| Weighted Average Price to Book Ratio | 13.62 |
| Weighted Median ROE | 7.19% |
| Weighted Median ROA | -14.00% |
| ROI (TTM) | -17.84% |
| Return on Investment (TTM) | -17.84% |
| Earning Yield | 0.0252 |
| LT Debt / Shareholders Equity | 8.869 |
As of March 31, 2025
Growth Metrics
| EPS Growth (1Y) | -9.66% |
| EPS Growth (3Y) | -26.81% |
| EPS Growth (5Y) | -12.63% |
| Sales Growth (1Y) | 15.38% |
| Sales Growth (3Y) | 14.43% |
| Sales Growth (5Y) | 24.65% |
| Sales per Share Growth (1Y) | 10.35% |
| Sales per Share Growth (3Y) | 6.04% |
| Operating Cash Flow - Growth Ratge (3Y) | -4.51% |
As of March 31, 2025
Fund Details
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:FBTCX", "name") |
| Broad Asset Class: =YCI("M:FBTCX", "broad_asset_class") |
| Broad Category: =YCI("M:FBTCX", "broad_category_group") |
| Prospectus Objective: =YCI("M:FBTCX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |